A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

To compare the efficacy and safety of tretinoin gel 0.05% to its vehicle when dosed once or twice daily in female subjects with rosacea.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Coria Laboratories, Ltd.
• Treatments: Tretinoin

Criteria

Inclusion Criteria:

• Female

• Age 18-65

• Diagnosed with classical, centrofacial, erythemato-telangiectatic rosacea

Exclusion Criteria:

• Male, females less than 18 years

• Females over 65 years

• No diagnosed rosacea